Parameter
| Biomarker | ctDNA (Circulating Tumor DNA) | Full name | Circulating tumor DNA | Molecular Type | Nucleic acid (fragments of DNA) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | 150-200 bp | Core Functional Dimensions | Diagnosis, prognosis, treatment response monitoring, MRD monitoring | |
| Disease | Cholangiocarcinoma (CCA) | Disease Subtypes | / | ||
| Organ | Bile duct/Liver | Test Sample / Technology Platform | Plasma/bile (NGS, ddPCR, dPCR) | ||
| Pathobiological Mechanisms | Tumor cells are released by apoptosis/necrosis, carrying tumor-specific mutations and abnormal methylation, reflecting tumor heterogeneity | ||||
| Clinical Availability Status | Research/clinical monitoring tools; In multi-center validation | ||||
| Notes and Dynamics | Bile ctDNA detection sensitivity (96.2%) and drivers mutation detection rate (54%) is significantly higher than the plasma (31.6%, 17%); VAF > 3.9% tip poor prognosis (OS 4.9 months) | ||||